Treating COPD is a burgeoning cash cow for big pharma, with GlaxoSmithKline (NYSE:GSK) the indication's dominant player. However, investors looking for the biotech behind Glaxo's next-gen COPD drugs may find a surprise in Theravance (NASDAQ: THRX). The company recently split in two, with the money it earns from its role in Anoro and Breo Ellipta continuing under the old ticker, while the drug-development arm is reborn as Theravance Biopharma (NASDAQ:TBPH).

In this episode of Market Check-Up, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass dive in to everything COPD and discuss why Theravance may end up disappointing investors.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.